Akita Biosciences

Akita Biosciences is a private, preclinical-stage biotech innovator based in San Diego, CA, with foundational IP from Harvard's Brigham and Women's Hospital. The company has developed a unique gel-forming nasal spray platform designed to overcome key limitations of traditional nasal delivery, such as short contact time and poor absorption. Its technology has a dual focus: enabling preventive health by blocking and neutralizing airborne threats, and enhancing the precision delivery of therapeutics. Akita has gained notable recognition, including being named to Fast Company's 2025 World's Most Innovative Companies list for its Profi Nasal Spray.

Proprietary gel-forming nasal spray platform designed to extend mucosal contact time (several hours vs. ~1 hour for standard sprays) and optimize absorption. It functions dually: as a protective barrier to capture/block airborne pathogens and allergens, and as an enhanced delivery vehicle for therapeutic agents.

In the consumer nasal spray space, Akita competes with numerous saline and herbal sprays, though its gel-based, long-acting technology is a differentiator. In the therapeutic nasal delivery platform arena, competitors include other specialty drug delivery companies and large pharma with internal capabilities. Akita's key competitive advantages are its strong academic IP, published data in a high-impact journal, and the multi-functional design of its platform.